TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05709964

Intervention type: OTHER
Intervention: Self-reported
Description: Self-reported height, weight, and neck circumference

Intervention type: OTHER
Intervention: Measured
Description: Height, weight, and neck circumference measured by the investigator.
Study: NCT06100822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 500 mg capsules of Metformin Extended Release

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 500 mg capsules of placebo pills
Study: NCT05482464

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Casein glycomacropeptide (CGMP)
Description: Casein glycomacropeptide (CGMP) supplementation for 3 weeks
Study: NCT05106322

Intervention type: OTHER
Intervention: intraoperative spectrometer scan
Description: intraoperative spectrometer scan (five scans on the left lobe) before clamping the aorta
Study: NCT06470256

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Palliative Hepatectomy
Description: Patients will receive TACE, HAIC, or 90Y-SIRT combined with Lenvatinib and Durvalumab. After receiving three months of combined treatment, patients in the SD or PD stage who have poor efficacy evaluated by imaging will undergo palliative hepatectomy.~Palliative Hepatectomy:① Intrahepatic metastasis: complete lesion resection of the main tumor on one side of the liver; ② Extrahepatic metastasis: complete lesion resection of intrahepatic lesions; ③ Merge portal vein tumor thrombus or hepatic vein tumor thrombus: remove the tumor thrombus and completely remove the intrahepatic lesions. And reduce the tumor burden by more than 90% through surgical resection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Starting two weeks post-surgery, patients began intravenous infusions of the PD-L1 monoclonal antibody, Durvalumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Three weeks post-surgery, patients commenced oral administration of Lenvatinib.
Study: NCT04389281

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: X-PACT
Description: X-PACT is comprised of a phosphor device, the drug methoxsalen sterile solution and X-ray energy. The dose of methoxsalen sterile solution per injection will vary per patient and will remained fixed across injections within each patient as it is based on the applicable tumor volume at baseline. Immediately after each injection of the combination product, patients will be exposed to an X-ray beam delivered via a LINAC (and thus targeted at the tumor) at a fixed dose to activate the combination product.
Study: NCT05281302

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neck muscle vibration
Description: Patient will receive neck muscle vibration during the first 15 minutes of occupational therapy. Vibratory stimulators will be fixed bilaterally on the skin over the belly of the trapezius muscles and fastened with straps. Only the left vibrator will be activated.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Neck muscle vibration + sham-tDCS
Description: Patient will receive neck muscle vibration during the first 15 minutes of occupational therapy.. Vibratory stimulators will be fixed bilaterally on the skin over the belly of the trapezius muscles and fastened with straps. Only the left vibrator will be activated.~Moreover, tDCS will be applied using an electrical stimulator (DC-STIMULATOR®, NeuroCare, Illmenau, Germany) through large saline-soaked sponge surface electrodes placed as follows: anode over the right (ipsilesional) posterior parietal cortex (P4 according to the International 10-20 EEG electrode placement system) and cathode over the left supraorbital region. The tDCS will be automatically turned off after 20 seconds. This allows the reproduction of the initial mild itching sensation at the beginning of active tDCS, thus ensuring that the patient stays blind to the activation status of the device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neck muscle vibration + anodal-tDCS
Description: Patient will receive neck muscle vibration during the first 15 minutes of occupational therapy. Vibratory stimulators will be fixed bilaterally on the skin over the belly of the trapezius muscles and fastened with straps. Only the left vibrator will be activated.~Moreover, tDCS will be applied using an electrical stimulator (DC-STIMULATOR®, NeuroCare, Illmenau, Germany) through large saline-soaked sponge surface electrodes placed as follows: anode over the right (ipsilesional) posterior parietal cortex (P4 according to the International 10-20 EEG electrode placement system) and cathode over the left supraorbital region. A continuous 2 mA current will be delivered for 20 minutes simultaneously to NMV stimulation. The stimulation will begin 5 minutes before the beginning of occupational therapy.
Study: NCT05257850

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-flow nasal therapy
Description: A high-flow nasal therapy for 30 minutes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-flow nasal therapy
Description: A high-flow nasal therapy for 30 minutes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Airflow directed to face by a fan
Description: A fan directed to the face for 30 minutes
Study: NCT05514314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: Within 4-6 weeks after surgery, Icotinib 125mg orally, TID was started for 2 years, or treatment was discontinued due to tumor recurrence or intolerance
Study: NCT05227521

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted H-GRASP feedback program
Description: Combination of the Home-Graded Repetitive Arm Supplementary Program with in home accelerometer-based feedback
Study: NCT06075836

Intervention type: OTHER
Intervention: Cases reading
Description: The reading will be done remotely via the Report and Image Quality Control site (www.RAIQC.com), an online platform allowing medical imaging viewing and reporting. Participants can work from any location, but the work must be done from a computer with internet access. For avoidance of doubt, the work cannot be performed from a phone or tablet.~The project is divided into two phases and participants are required to complete both phases. The estimated total involvement in the project is up to 20-24 hours.~Phase 1: Time allowed: 2 weeks~- Review 500 chest X-rays and express a clinical opinion through a structured reporting template (multiple choice, no open text required).~Rest/washout period of 2 weeks.~Phase 2 - Time allowed: 2 weeks~- Review 500 chest X-rays together with an AI report for each case and express your clinical opinion through the same structured reporting template used in Phase A.

Intervention type: OTHER
Intervention: Ground truthing
Description: Two consultant thoracic radiologists will independently review the images to establish the 'ground truth' findings on the CXRs, where a consensus is reached this will then be used as the reference standard. In the case of disagreement, a third senior thoracic radiologist's opinion (\>20 years experience) will undertake arbitration. A difficulty score will be assigned to each abnormality by the ground truthers using a 4-point Likert scale (1 being easy/obvious to 4 being hard/poorly visualised).
Study: NCT05973929

Intervention type: OTHER
Intervention: Screen for movement disorder and correlates it with MRI findings.
Description: * To determine the prevalence of movement disorders in MS patients.~* To know the clinical type of movement disorders occurring with multiple sclerosis patients and the MRI finding of those patients.~* To find the correlation between the movement disorder and the different types of MS.
Study: NCT05687331

Intervention type: PROCEDURE
Intervention: knee arthrocentesis
Description: arthrocentesis of the knee joint to gather a synovial fluid sample

Intervention type: PROCEDURE
Intervention: knee arthrocentesis
Description: arthrocentesis of the knee joint to gather a synovial fluid sample

Intervention type: PROCEDURE
Intervention: venipuncture
Description: Peripheral venipuncture to gather a blood sample

Intervention type: PROCEDURE
Intervention: venipuncture
Description: Peripheral venipuncture to gather a blood sample

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI-scan
Description: MRI-scan of the knee

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI-scan
Description: MRI-scan of the knee

Intervention type: DIAGNOSTIC_TEST
Intervention: Physical examination
Description: Physical examination of the injured knee

Intervention type: DIAGNOSTIC_TEST
Intervention: Physical examination
Description: Physical examination of the injured knee

Intervention type: OTHER
Intervention: KOOS questionnaire
Description: KOOS questionnaire of the injured knee

Intervention type: OTHER
Intervention: KOOS questionnaire
Description: KOOS questionnaire of the injured knee
Study: NCT04530942

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation(Active)
Description: DBS On with the optiomal parameters

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation(Active)
Description: DBS On with the optiomal parameters

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation(Sham)
Description: DBS On with 0V Amplitude

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation(Sham)
Description: DBS On with 0V Amplitude
Study: NCT04479579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 milligram
Description: apixaban 2.5 milligram twice daily from discharge until postoperative day 29 +/- 1 day
Study: NCT04562207

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Screening for respiratory virus infection
Description: Nasopharyngeal swab for screening for respiratory virus infection before surgery
Study: NCT06159868

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured physiotherapy and rehabilitation
Description: Comprehensive baseline assessment of function and nutrition using indirect calorimetry to identify nutritional requirements, to create and individualised plan for followed by daily targeted mobility retraining, exercise and nutrition.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard ward based care provided by usual care teams
Study: NCT05241990

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Practice Facilitation
Description: A practice coach will offer tools, resources, hands-on guidance, and content expertise to assist sites in offering a stepped care model of alcohol treatment to patients with unhealthy alcohol use.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol Stepped Care
Description: Based on severity of alcohol use, individuals receive brief alcohol intervention delivered in person or by computer, cognitive behavioral therapy by person or computer, or pharmacotherapy for alcohol use disorder
Study: NCT05288790

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Dietary supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo sachet
Study: NCT05030870

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Capnography monitoring
Description: Standard monitoring and capnographic monitoring.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard monitoring
Description: Standard monitoring but no capnographic monitoring

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard monitoring
Description: Standard monitoring but no capnographic monitoring
Study: NCT06018415

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early time-restricted eating (eTRE)
Description: The eTRE group is instructed to consume all calories in early 8h eating window,

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Late time-restricted eating (lTRE)
Description: The lTRE group is instructed to consume all calories in late 8h eating window.
Study: NCT05703971

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: quaratusugene ozeplasmid
Description: Quaratusugene ozeplasmid is an experimental nonviral immunogene therapy utilizing the TUSC2 gene, designed to target cancer cells by interrupting cell signaling pathways that allow cancer cells to grow, reestablishing pathways that promote cancer cell death and modulating the immune response against cancer cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: quaratusugene ozeplasmid
Description: Quaratusugene ozeplasmid is an experimental nonviral immunogene therapy utilizing the TUSC2 gene, designed to target cancer cells by interrupting cell signaling pathways that allow cancer cells to grow, reestablishing pathways that promote cancer cell death and modulating the immune response against cancer cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: atezolizumab
Description: Atezolizumab is a monoclonal antibody that belongs to a class of drugs that binds to the programmed death-receptor 1 ligand 1 (PD-L1), blocking the PD-1/PD-L1 pathway, thereby removing inhibition of the immune response, potentially breaking peripheral tolerance and inducing immune-mediated adverse reactions.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: atezolizumab
Description: Atezolizumab is a monoclonal antibody that belongs to a class of drugs that binds to the programmed death-receptor 1 ligand 1 (PD-L1), blocking the PD-1/PD-L1 pathway, thereby removing inhibition of the immune response, potentially breaking peripheral tolerance and inducing immune-mediated adverse reactions.
Study: NCT06082986

Intervention type: DRUG
Intervention: Ustekinumab
Description: No interventions will be administered as a part of this study. Participants received ustekinumab as per their routine clinical practice.
Study: NCT05309187

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IO-202
Description: IO-202 given as monotherapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IO-202 + pembrolizumab combination therapy
Description: IO-202 and fixed dose pembrolizumab combination therapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RP2D of IO-202 + pembrolizumab combination therapy in multiple solid tumor types
Description: Expansion cohorts of the RP2D of IO-202 and fixed dose pembrolizumab combination therapy in multiple tumor types.
Study: NCT06183840

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glutack
Description: Three ports are used (1x11 mm and 2x5 mm) and after adhesiolysis and the field prepared, the defect is measured with a local standard in a craneo-caudal and transversal directions. Then, the defect is closed with a 2-0 caliber barbed suture following its biggest axis. A Dynamesh IPOM previously hydrated (2-3 min) is introduced throughout the 11mm trocar and extended. After this maneuver, mesh fixation is performed depending on the randomized arm: Glutack

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional
Description: Three ports are used (1x11 mm and 2x5 mm) and after adhesiolysis and the field prepared, the defect is measured with a local standard in a craneo-caudal and transversal directions. Then, the defect is closed with a 2-0 caliber barbed suture following its biggest axis. A Dynamesh IPOM previously hydrated (2-3 min) is introduced throughout the 11mm trocar and extended. After this maneuver, mesh fixation is performed depending on the randomized arm: Traumatic fixation
Study: NCT06005727

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transanal ice pack
Description: A condom is filled with 100ml of water and frozen to serve as a transanal ice pack. It is covered by sterile plastic dressing and applied to the hemorrhoidectomy wound for 1 minute after surgery is completed.
Study: NCT05885100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eleveld Model
Description: Target plasma propofol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eleveld Model
Description: Target plasma propofol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eleveld Model
Description: Target plasma propofol
Study: NCT04639583

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near-infrared spectroscopy (NIRS) utilization
Description: The NIRS devise will be applied so that cerebral regional oxygen saturation (cRSO2) can be measured.
Study: NCT05348174

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality Assisted Guided Imagery (VRAGI)
Description: The visual landscape consists of a computer-generated immersive virtual world with nature-based imagery (i.e., trees, birds, mountains, water) and accompanying soundscapes with guided imagery.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Virtual Reality Assisted Guided Imagery (VRAGI)
Description: The visual landscape consists of a computer-generated immersive virtual world with nature-based imagery (i.e., trees, birds, mountains, water) and accompanying soundscapes with guided imagery.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality Assisted Guided Imagery (VRAGI)
Description: The visual landscape consists of a computer-generated immersive virtual world with nature-based imagery (i.e., trees, birds, mountains, water) and accompanying soundscapes with guided imagery.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Virtual Reality Assisted Guided Imagery (VRAGI)
Description: The visual landscape consists of a computer-generated immersive virtual world with nature-based imagery (i.e., trees, birds, mountains, water) and accompanying soundscapes with guided imagery.
Study: NCT06240832

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy exercise
Description: Endurance, strength and stretching training in Chronic liver disease children
Study: NCT05257850

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Airflow directed to face by a fan
Description: A fan directed to the face for 30 minutes
Study: NCT05290714

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mentalization-Based Treatment for Children (MBT-C)
Description: MBT-C will involve 12 paralel individual sessions with the parents and children separately conducted by two different therapists.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parenting and Social Skills Group
Description: Parenting/social skills groups will be co-led by two therapists and involve 12 group therapy sessions with the parents and their children separately (10 parents and children per group).
Study: NCT06090734

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: My Voice
Description: The web intervention educates patients about their illness and supports them to make their own Advance Care Planning decisions, update these decisions frequently as their clinical condition changes, and to make the ACP process easier and more accessible. The intervention aims to shift implementation of ACP from a provider-led one-time model to a patient-led dynamic model.
Study: NCT05780307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMM2520
Description: IMM2520 will be administered once a week intravenously at Day 1, Day8, Day 15 and Day 22 each cycle for up to 48 weeks.
Study: NCT05455112

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RUTI® Vaccine
Description: One subcutaneous injection of RUTI 25µg FCMtb

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One subcutaneous injection of saline
Study: NCT05195294

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LioCyx-M
Description: HBV antigen specific TCR redirected T cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LioCyx-M
Description: HBV antigen specific TCR redirected T cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 12 mg once daily for patients ≥60 kg, 8 mg for patients \<60kg by oral
Study: NCT05957991

Intervention type: DRUG
Intervention: Metformin Hydrochloride tablet
Description: Treatment with metformin

Intervention type: DRUG
Intervention: Metformin Hydrochloride tablet
Description: Treatment with metformin

Intervention type: DRUG
Intervention: Placebo
Description: Treatment with placebo

Intervention type: DRUG
Intervention: Placebo
Description: Treatment with placebo

Intervention type: BEHAVIORAL
Intervention: Lifestyle intervention
Description: Changing behaviour on diet and excersise

Intervention type: BEHAVIORAL
Intervention: Lifestyle intervention
Description: Changing behaviour on diet and excersise

Intervention type: BEHAVIORAL
Intervention: No lifestyle intervention
Description: No changes in behaviou on diet and excersise

Intervention type: BEHAVIORAL
Intervention: No lifestyle intervention
Description: No changes in behaviou on diet and excersise
Study: NCT04851028

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Music therapy is a non-pharmacological intervention, in which music and its elements are used professionally as an intervention in medical, educational, and everyday environments with individuals, groups, families, or communities who seek to optimize their quality of life and improve their physical, social, communicative, emotional, intellectual, and spiritual health and wellbeing. This therapy has shown to provide significant benefits for individuals with cognitive decline living in care homes, enhancing social-cognitive functions and reducing behavioural symptoms (Brotons \& Koger, 2000; Hsu et al., 2015; Zhang et al., 2017).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Music therapy is a non-pharmacological intervention, in which music and its elements are used professionally as an intervention in medical, educational, and everyday environments with individuals, groups, families, or communities who seek to optimize their quality of life and improve their physical, social, communicative, emotional, intellectual, and spiritual health and wellbeing. This therapy has shown to provide significant benefits for individuals with cognitive decline living in care homes, enhancing social-cognitive functions and reducing behavioural symptoms (Brotons \& Koger, 2000; Hsu et al., 2015; Zhang et al., 2017).
Study: NCT05462015

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: elastic-band exercises
Description: The training content includes 5 minutes of warm-up exercise, 20 minutes of elastic-band resistance training, and 10 minutes of cool-down exercise.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: regular rehabilitation
Description: The training content includes 5-minute warm-up exercise, 20-minute upper and lower extremity muscle strengthening, and 10-minute cool-down exercise
Study: NCT06436651

Intervention type: OTHER
Group type: OTHER
Intervention: Digital Storytelling
Description: 4 stages of digital storytelling will be implemented.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital Storytelling
Description: 4 stages of digital storytelling will be implemented.